Navigation Links
FDA Approves New Treatment for Advanced Form of Kidney Cancer
Date:10/19/2009

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.

Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney. In 2009, approximately 49,000 people were diagnosed with renal cell carcinoma and 11,000 people died from the disease.

"The last five years have seen dramatic improvements in treatment options for patients with kidney cancer. Before 2005, the options available offered only limited effectiveness," said Richard Pazdur, M.D., director, Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.

The five other drugs approved for kidney cancer and their approval dates are: Sorafenib (December 2005), Sunitinib (January 2006), Temsirolimus (May 2007), Everolimus (March 2009), and Bevacizumab (July 2009).

The safety and effectiveness of Votrient was evaluated in a 435-patient study that examined a patient's progression-free survival - the length of time, following enrollment in the study, before the tumor began growing again or before the patient died. Progression-free survival averaged 9.2 months for patients receiving Votrient compared to 4.2 months for patients who did not receive the drug.

Adverse reactions included diarrhea, high blood pressure, hair color changes, nausea, loss of appetite, vomiting, fatigue, weakness, abdominal pain and headache. Votrient can also cause severe and fatal liver toxicity. Health care professionals should order blood tests to monitor liver function before and during treatment with the drug. Since Votrient can harm a fetus, it should not be used during pregnancy.

The drug has also been associated with heart rhythm irregularities. Patients receiving Votrient should be monitored with periodic electrocardiograms, which measure heart rhythm, and blood tests to monitor electrolytes since an electrolyte imbalance can lead to an irregular heart rhythm.

Votrient is manufactured by London-based GlaxoSmithKline.

Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
2. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
3. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
4. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
5. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
6. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
7. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
8. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
9. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
10. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
11. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 Hutchison China ... focused on the highly lucrative global oncology and ... of potential first-in-class or best-in-class tyrosine kinase inhibitor ... with strategic partners. HCM,s profitable Chinese healthcare business ... We expect progress of the mid-to-late-stage pipeline during ...
(Date:5/27/2016)... , May 27, 2016 The ... manufacturers, health insurance companies all falling under its umbrella.  ... companies. While not often talked about, these healthcare companies ... United States is by far the largest ... Medical Isotope Corp. (OTC: ADMD), Nutranomics Inc. (OTC: NNRX), ...
(Date:5/26/2016)... 26, 2016 TARE (Transarterial ... Cost Savings and Overall Decreased Use of ... an international specialist healthcare company, has today announced ... Annual Meeting of ISPOR (International Society for Pharmacoeconomics ... carcinoma (HCC) using yttrium-90 glass microspheres is associated ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... ... (IP) to its specialty academic programs. , Answering to the increasing demand for ... programs in health law, and environmental and land use law. ,  , “The ...
(Date:5/26/2016)... Pompano Beach, Florida (PRWEB) , ... May 26, 2016 , ... ... Green House® Project offering a new model of care for living and ... on three core values: Meaningful Life in a Real Home provided by Empowered Staff. ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... MadgeTech will ... designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With products ... reliable monitoring solutions trusted by government agencies, including NASA. , In 2012, NASA ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising ... 550 employees of Sun Health Senior Living (SHSL) may not share those ... doctor and prescription copays for the year, while holding the line on increasing their ...
(Date:5/26/2016)... Indiana (PRWEB) , ... May 26, 2016 , ... ... provider of healthcare supply chain solutions, today announced the organization has earned its ... meets international standards and is compliant with all rules and policies associated with ...
Breaking Medicine News(10 mins):